GKOS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

129.46M

+22.71%

-0.210

-47.62%

131.68M

+23.46%

-0.187

-15.12%

149.41M

+20.38%

-0.113

-52.95%

Estimates Revision

The market is revising Upward the revenue expectations for Glaukos Corporation (GKOS) for FY2025, with the revenue forecasts being adjusted by 1.92% over the past three months. During the same period, the stock price has changed by 36.77%.

Revenue Estimates for FY2025

Revise Upward

+1.92%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-8.42%

In Past 3 Month

Stock Price

Go Up

+36.77%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast GKOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GKOS is 117.30 USD with a low forecast of 72.00 USD and a high forecast of 165.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

0 Hold

1 Sell

Strong Buy

Current: 0.000

Low

72.00

Averages

117.30

High

165.00

Current: 0.000

Low

72.00

Averages

117.30

High

165.00

Goldman Sachs

Buy

maintain

$112 -> $138

2026-01-09

New

Reason

Goldman Sachs

Price Target

$112 -> $138

2026-01-09

New

maintain

Buy

Reason

Goldman Sachs raised the firm's price target on Glaukos to $138 from $112 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.

Stephens

Overweight

maintain

$115 -> $145

2026-01-02

Reason

Stephens

Price Target

$115 -> $145

2026-01-02

maintain

Overweight

Reason

Stephens raised the firm's price target on Glaukos to $145 from $115 and keeps an Overweight rating on the shares. The firm, which slightly moderated its outlook for non-iDose U.S. glaucoma revenue, but modestly increased its iDose revenue expectations, views Glaukos as "one of the best multi-year medtech growth stories" entering 2026 as iDose is benefiting from expanding reimbursement, deeper utilization, a growing surgeon base, and a long runway of untreated and uncontrolled glaucoma patients.

UBS

Buy

maintain

$140 -> $145

2025-12-23

Reason

UBS

Price Target

$140 -> $145

2025-12-23

maintain

Buy

Reason

UBS raised the firm's price target on Glaukos to $145 from $140 and keeps a Buy rating on the shares.

Truist

Buy

upgrade

$120 -> $145

2025-12-18

Reason

Truist

Price Target

$120 -> $145

2025-12-18

upgrade

Buy

Reason

Truist raised the firm's price target on Glaukos to $145 from $120 and keeps a Buy rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.

Citi

Joanne Wuensch

Buy

maintain

$113 -> $125

2025-12-11

Reason

Citi

Joanne Wuensch

Price Target

$113 -> $125

2025-12-11

maintain

Buy

Reason

Citi analyst Joanne Wuensch raised the firm's price target on Glaukos to $125 from $113 and keeps a Buy rating on the shares. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is "bouncing off its lows," and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index "remains undervalued and underappreciated." The firm expects a rebound next year due to company catalysts and sector rotation.

Needham

Buy

upgrade

$117 -> $125

2025-12-09

Reason

Needham

Price Target

$117 -> $125

2025-12-09

upgrade

Buy

Reason

Needham raised the firm's price target on Glaukos to $125 from $117 and keeps a Buy rating on the shares. The firm's calls with three doctors, including two using Photrexa who are looking at starting Epioxa and one who is doing off-label Epi-On, has left it more positive on Glaukos given that there likely is near-term upside to Photrexa numbers since there is no evidence of "warehousing" and because Epioxa could increase doctors' capacity, enabling them to potentially treat more patients, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Glaukos Corp (GKOS.N) is -198.99, compared to its 5-year average forward P/E of -65.55. For a more detailed relative valuation and DCF analysis to assess Glaukos Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-65.55

Current PE

-198.99

Overvalued PE

-18.17

Undervalued PE

-112.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-551.55

Current EV/EBITDA

-1373.43

Overvalued EV/EBITDA

2375.09

Undervalued EV/EBITDA

-3478.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

11.09

Current PS

11.13

Overvalued PS

14.33

Undervalued PS

7.84

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 256.76% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 318.02% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 256.76% over the last month.

Sold

Bought

GKOS News & Events

Events Timeline

No data

News

7.0

01-03Yahoo Finance

Glaukos Forecasts Profitability by 2027 with 56% Annual Growth Rate

6.0

01-02Benzinga

BTIG Raises Hudson Pacific Price Target to $26

4.5

2025-12-24Barron's

S&P 500 Futures Steady in Pre-Market Session; United Therapeutics and Intel Underperform

People Also Watch

Frequently Asked Questions

What is Glaukos Corp (GKOS) stock price today?

The current price of GKOS is 112.92 USD — it has decreased -1.08 % in the last trading day.

What is Glaukos Corp (GKOS)'s business?

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

What is the price predicton of GKOS Stock?

What is Glaukos Corp (GKOS)'s revenue for the last quarter?

Glaukos Corp revenue for the last quarter amounts to 133.54M USD, increased 38.14 % YoY.

What is Glaukos Corp (GKOS)'s earnings per share (EPS) for the last quarter?

Glaukos Corp. EPS for the last quarter amounts to -0.28 USD, decreased -28.21 % YoY.

What changes have occurred in the market's expectations for Glaukos Corp (GKOS)'s fundamentals?

How many employees does Glaukos Corp (GKOS). have?

Glaukos Corp (GKOS) has 995 emplpoyees as of January 10 2026.

What is Glaukos Corp (GKOS) market cap?

Today GKOS has the market capitalization of 6.49B USD.